Page 846 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

824 Index

Gingival hyperplasia, 447 Ground substance, from tumor, 130 Hemangiosarcoma (HSA), 19, 773
Gingival melanoma, 370, 370f Growth factor in cats, 555
role of, 41
comparative aspects, 778
GIST. see Gastrointestinal stromal tumor
VetBooks.ir Gland tumor Growth factor receptor conclusion, 778
types of, 42t
apocrine gland of anal sac, 134
diagnostic techniques and workup,
mammary, 133–134 role of, 41 774–775, 775f, 775t
perianal, 134 types of, 42t in dogs, 551
prostate gland, 134 Growth-promoting gene, 4–5 history and clinical signs, 774
salivary, 133 Growth signal, self-sufficiency of, 4–5, 45–46 immunohistochemical markers/panels for,
types of, 359 Growth signal pathway, 264 72t–73t
apocrine gland carcinoma, 359 Growth suppressors, evading, 5–6 incidence and risk factors, 773
apocrine gland/solid-cystic apocrine GTCT. see Granulosa-theca cell tumor with malignancy criteria, 131f
ductal adenoma, 359 GTP. see Guanosine triphosphate pathology and natural behavior, 773–774,
sebaceous epithelioma, 359 GTV. see Gross tumor volume 774f
sebaceous gland carcinoma, 359 Guanosine triphosphate (GTP), 42 prognosis, 777–778
Gliomatosis cerebri, 666t canine, 777–778, 778t
Glomerular filtration rate (GFR), 189f H feline, 778
Glomerulonephritis, 106 HAC. see Hyperadrenocorticism in spinal cord, 666t
tumors associated with, 99b Hair follicle tumor of third eyelid, 677f
Glucagonoma, 585 characteristics of treatment, 776–777, 776f
Glucocorticoid, 296–297 infundibular keratinizing acanthoma, alternative therapies, 777
Glucocorticoid-induced TNF receptor family- 358 chemotherapy, 776
regulated gene (GITR), 233 malignant pilomatricoma, 359 immunotherapy, 776–777
Glucose, parenteral solutions proportions for, malignant trichoepithelioma, 359 radiation therapy, 777
306 pilomatricoma, 359 surgery, 776
Glucose transporter (GLUT-1), 9 treatment of, 358 targeted therapies, 777
Glutathione S-transferase, 185 trichoblastoma, 358, 358f Hematologic manifestation, of cancer
Glycoprotein BerEP4, 356 trichoepithelioma, 358–359 anemia, 99b, 102–103
Glycosaminoglycans, dose and effects of, tricholemmoma, 358 coagulopathies and DIC, 99b, 104
293t–294t identification of, 132–133 erythrocytosis, 99b, 103
GM-CSF. see Granulocyte-macrophage Hayflick limit, 6 hyperglobulinemia, 99b, 102
colony-stimulating factor Hazard waste landfill, 92 hyperviscosity syndrome, 102
GMP. see Good manufacturing practice HDDST. see High-dose dexamethasone neutrophilic leukocytosis, 99b, 103
Gonad, benign/malignant tumors of, 64t suppression test thrombocytopenia, 99b, 103–104
Good clinical practice (GCP), 344 H&E. see Hematoxylin and eosin Hematopoietic cell, benign/malignant tumors
Good manufacturing practice (GMP), 344 Head-to-head comparison studies, in canine of, 64t
Goodman, Louis, 182 osteosarcoma, 544 Hematopoietic tumors, 688–772
G-protein signal transducer, 42t Health-related quality of life (HRQOL), 288 canine acute myeloid leukemia,
Grading Heart, neoplasia of, 787 myeloproliferative neoplasms, and
criteria reflecting molecular mechanism, comparative aspects, 791 myelodysplasia, 730–739
67–69, 69t diagnostic techniques and workup, canine lymphoma and lymphocytic
purpose of, 67 788–790, 789f–790f leukemias, 688–715
Granular cell myoblastoma, 446, 446f history and clinical signs, 788, 788t feline lymphoma and leukemia, 715–730
“Granular cell tumor”, 140 incidence and risk factors, 787 myeloma-related disorders, 739–752
Granulation tissue, imprint of, 137f pathology and natural behavior, 787–788 Hematoxylin and eosin (H&E), 385–386
Granulocyte colony-stimulating factor prognosis, 791 Hemipelvectomy, for bone tumors, 541
(G-CSF), 103 therapy, 790–791 Hemophagocytic histiocytic sarcoma (HHS),
Granulocyte-macrophage colony-stimulating Heat fixation, 128–129 792t, 797
factor (GM-CSF), 103 Heat shock protein (HSP), in canine cell characteristics in, 144
Granulosa-theca cell tumor (GTCT) osteosarcoma, 533 Hemorrhage, of aspirated sample, 130
in cats, 598 Heat shock protein 90 (HSP 90), 271–272 Hepatitis B, hepatocellular carcinoma and, 26
in dogs Heat shock protein 90 (HSP 90) inhibition Hepatitis C, hepatocellular carcinoma
epithelial ovarian tumor expression of, activity of, 271 and, 26
597 molecules targeted by, 271t Hepatobiliary tumors, 454–455, 454f–455f,
metastatic rate of, 597–598 tumor cell sensitivity to, 271 454t
ultrasound of, 599f Heat shock protein 90 (HSP 90) inhibitor, 271 clinicopathologic abnormalities of, 457t
Gray (Gy), 209 Hedgehog-GLI signaling pathways, canine comparative aspects for, 460
Grief and loss, providing support for, 318 osteosarcoma and, 526–527 diagnostic techniques and workup for,
Grooming, 14 Hedgehog signaling pathway, 354 457–458
Gross tumor volume (GTV), 215–216 Hemangioma, cell characteristics in, 138–139 imaging for, 457–458
Ground-glass nodule, computed tomography Hemangiopericytoma, 406 laboratory tests, 457, 457t
of, 117f fine-needle aspiration of, 139f history and clinical signs of, 456–457